Compare Novartis AG (NVS) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Valero Energy Corporation — how do they compare? Novartis AG trades at $138.16 (market cap $262.64B), while Valero Energy Corporation trades at $389.98 (market cap $110.23B). The key difference: Novartis AG is far larger — about 2.4× Valero Energy Corporation's market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| NVS | VLO | |
|---|---|---|
Market Cap | $262.64B | $110.23B |
Sector | Health | Energy |
52-Week High | $168.62 | $388.95 |
52-Week Low | $121.80 | $156.39 |
Enterprise Value | $303.97B | $113.71B |
Dividend Yield | 3.44% | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Valero Energy (VLO) trades at $382.85, up 3.27% today, reflecting strong momentum amid favorable refining conditions. The stock exhibits a bullish technical trend, with recent earnings beats and a Zacks Rank #1 (Strong Buy) as of September 9, 2026. Fundamentals show robust profitability with a 29.31% ROE, though revenue has declined from $176.4B in 2022 to $122.7B in 2025. Analyst consensus is bullish with a $345.55 price target, and the company maintains a solid balance sheet with $4.66B in cash.
VLO's outlook is supported by tight fuel supplies and healthy demand, with projected 2026 net income of $7.2B. Key risks include volatile energy prices and potential regulatory pressures. The stock offers growth potential but faces headwinds from revenue declines and geopolitical factors affecting the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
